Organogenesis stock holds at EUR 0.73 ahead of Nov. 5 results

Published on 10/30/2026 at 03:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organogenesis stock is unchanged before the company reports third-quarter results on November 5. New clinical data supports PuraPly AM.

Clinical data and upcoming results

Organogenesis said the PREPARE trial met its primary endpoint in hard-to-heal diabetic foot ulcers.
The company is scheduled to report third-quarter fiscal 2026 results on November 5.
The study results support further discussions about coverage for PuraPly AM.

ORGO, US68621F1021, Illustration mit AI erstellt.

Organogenesis stock was quoted at 0.73 Euro on Thursday, October 29, at 22:59:30 Berlin time, according to Lang & Schwarz. The quote was unchanged from the previous close in the same data set. The company is due to report its third-quarter fiscal 2026 results on November 5.

PREPARE trial met its endpoint

On October 12, Organogenesis announced the publication of previously released PREPARE results in the Journal of Wound Care. In the GlobeNewswire release, the company said the prospective, multicenter, randomized trial achieved its primary endpoint.

The study compared PuraPly AM plus standard of care with standard of care alone in hard-to-heal diabetic foot ulcers. Organogenesis said the combination produced statistically significant improvements in wound closure at 12 weeks. The release describes the findings as clinical evidence supporting PuraPly AM in a difficult-to-treat chronic wound population.

Coverage remains an open question

Chief Operating Officer Patrick Bilbo said the company expects the evidence to form the basis for future coverage decisions for PuraPly AM. That statement is forward-looking and does not represent an announced reimbursement decision. Investors will therefore have to distinguish between the trial result and any later effect on product access, coverage or revenue.

Organogenesis focuses on regenerative medicine products for advanced wound care as well as surgical and sports medicine. The November 5 report should provide the next scheduled update on operating performance and management's corporate outlook.

A real-time quote of Organogenesis Holdings stock is available in the stock snapshot.

Market participants can place the company-specific developments in the broader context of the S&P 500 and the wider US equity market.

More news and analyses on Organogenesis Holdings stock are available in the topic overview.